Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


1234>>>
77 Items
Title  Creator  Group name  Publishing year 
Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia Xiong et al. EquipeAP 2021
[Indications and outlooks of radiohormonal therapy of high-risk prostate cancers] Latorzeff et al. EquipeAP Feb 11, 2020
[From fibrogenesis towards fibrosis: Pathophysiological mechanisms and clinical presentations] Maria et al. EquipeAP Feb 08, 2020
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells Bourillon et al. EquipeAP Jan 17, 2020
Five-year results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial Bosma et al. EquipeAP Jan 24, 2020
[Treatment of primary disease (breast, non-small cell lung and prostate cancers) with irradiation in case of de novo metastatic cancer] Latorzeff et al. EquipeAP Sep 06, 2019
[Treatment of oligometastatic or oligoprogression cancer] Bourgier et al. EquipeAP Sep 05, 2019
[Radioimmunotherapy: the reasons for confidential clinical use and hope for development] Barbet et al. EquipeAP Dec 2019
[Predictive assays for responses of tumors and normal tissues in radiation oncology] Riou et al. EquipeAP Aug 23, 2019
[Players from the program "Investments for the Future": MAbImprove MabEx] Larivière et al. EquipeAP Dec 2019
[Mimicking polyclonal immune response in therapy: from combination of two monoclonal antibodies to oligoclonal antibody-based mixtures] Larbouret et al. EquipeAP Dec 2019
[Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?] Riou et al. EquipeAP Aug 20, 2019
[Individual modification of the dose, volume and fractionation of breast radiotherapy] Bourgier et al. EquipeAP Aug 01, 2019
[Antibodies, tools of choice for fluorescence-guided surgery] Pèlegrin et al. EquipeAP Dec 2019
[A word from the coordinators] Pèlegrin et al. EquipeAP Dec 2019
Tracking, gating, free-breathing, which technique to use for lung stereotactic treatments? A dosimetric comparison Prunaretty et al. EquipeAP 2019 Jan-Feb
Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients Framery et al. EquipeAP 2019
The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice Montero-Luis et al. EquipeAP Jun 2019
Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France Martineau et al. EquipeAP 07 2019
Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer Amestoy et al. EquipeAP Jul 16, 2019
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer Seibold et al. EquipeAP May 27, 2019
Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity Lacombe et al. EquipeAP Aug 09, 2019
Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients With Head and Neck Cancer: Results of the Biology-Driven Phase 2 Clinical Trial Pravacur Bourgier et al. EquipeAP 06 01, 2019
Multi-centre technical evaluation of the radiation-induced lymphocyte apoptosis assay as a predictive test for radiotherapy toxicity Talbot et al. EquipeAP Sep 2019
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells Le Clorennec et al. EquipeAP Aug 23, 2019
1234>>>
77 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés